

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6081787

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	BONGCHEOL KIM	04/24/2020
	JAE-KEUN LEE	04/24/2020
	DONG SIK KIM	04/24/2020
RECEIVING PARTY DATA		
Name:	NEURACLE SCIENCE CO., LTD.	
Street Address:	SANHAKGWAN 702-2, ANAM-RO 145	
City:	SEONGBUK-GU, SEOUL	
State/Country:	KOREA, REPUBLIC OF	
Postal Code:	02841	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	16626621	
CORRESPONDENCE DATA		
Fax Number:	(202)371-2540	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(202) 371-2600	
Email:	TTOPSSecretary5@sternekessler.com,dchoo@sternekessler.com	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	
Address Line 1:	1100 NEW YORK AVENUE, N.W.	
Address Line 4:	WASHINGTON, D.C. 20005	
ATTORNEY DOCKET NUMBER:	3763.0040002	
NAME OF SUBMITTER:	DANIEL K. CHOO	
SIGNATURE:	/Daniel K. Choo #72,039/	
DATE SIGNED:	04/28/2020	
Total Attachments: 2		
source=2020-04-28-Assignment-3763-0040002#page1.tif		
source=2020-04-28-Assignment-3763-0040002#page2.tif		

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Bongcheol KIM**, **Jae-Keun LEE**, and **Dong Sik KIM** and hereby sell and assign to **Neuracle Science Co., LTD.**, a corporation formed under the laws of Seoul, Republic of Korea, whose mailing address is Sanhakgwan 702-2, Anam-ro 145, Seongbuk-gu, Seoul, Republic of Korea 02841 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING FIBROSIS** for which application(s) for patent in the United States of America has a filing date of June 27, 2018 (*also known as United States Application No. 16/626,621, which is the U.S. National Phase of Int'l Appl. No. PCT/IB2018/054779*), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.




The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 156725** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 156725** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: <u>24 April 2020</u>	Signature of Inventor: <u></u> Bongcheol KIM
Date: <u>24 Apr 2020</u>	Signature of Inventor: <u></u> Jae-Keun LEE
Date: <u>24 Apr 2020</u>	Signature of Inventor: <u></u> Dong Sik KIM

14842017_1